Report copyright - RAISING EXPECTATION IN ALK+ NSCLC TREATMENT · (95% CI: 12.6-NR; n=73) 16.6-month median intracranial DOR d,f (95% CI: 3.7-16.6; n=12) 67% intracranial ORRd,f (95% CI: 41-87; n=18)
Please pass captcha verification before submit form